Rexin G
| Identifiers | |
|---|---|
| CAS Number | |
Rexin G is a tumor-targeted
anti-tumor activity and increases both overall survival time and the survival rates in the majority of patients.[2]
History
While the molecular cloning and the characterization of the G1
target delivery system began in 1995, though it was not possible to implement int until late 1997. The initial concepts behind Rexin-G was first possible in 2002 and the first toxicology studies of the drug began in 2004. Studies into the effective of the drug soon began after the drug was found to be non-toxic in both mammals in the 2005. With the introduction of clinical grade vectors in the 2006, the drug soon saw widespread testing in late 2006.[1]
Rexin-G was officially accepted by Philippine
References
- ^ S2CID 34367291.
- ^ "Rexin-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial". Drugs.com. January 2009. Retrieved 18 January 2015.
- ^ "Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer". cancer.gov. Retrieved 18 January 2015.
 | This oncology article is a stub. You can help Wikipedia by expanding it. |